As IBM was preparing to announce yet another milestone achievement, this year receiving 9,100 U.S. patents in 2018, I had the opportunity to sit down for an on the record conversation with Mark Ringes, Vice President and Assistant General Counsel for IBM, and Manny Schecter, Chief Patent Counsel for IBM. Our conversation was wide-ranging, but what appears below specifically relates to IBM’s innovation leadership and quest to patent as much of its technology and innovation as possible. We discuss how IBM’s commitment to innovation and how the company is unafraid of pursuing the hardest, riskiest innovations because those will be the most valuable innovations in the future. Of course, even IBM is constrained with a budget, and must report to shareholders, so the philosophy is to obtain patents in a variety of areas and allow the research, technology and market realities dictate where future resources, and company efforts, are placed.
The post In Pursuit of the Hardest, Riskiest and Most Valuable Innovation appeared first on IPWatchdog.com | Patents & Patent Law.
Patent
- Enablement
- Fee Shifting
- Litigation
- Other Barks & Bites for Friday, March 31: Japan Restricts Chip-Making Exports, Ocado Scores UK High Court Win in Robotic Warehousing Case, and Judge Rejects Fair Use Defense for Internet Archive
- U.S. Government Sides with Teva in Skinny Label SCOTUS Fight
- Industry, NGOs Spar Over Need to Extend TRIPS COVID IP Waiver at ITC Hearing
- Software-Related U.S. Patent Grants in 2022 Remained Steady While Chinese Software Patents Rose 8%
- The Truth Leaks Out: Justices Struggle with the Science, Sanofi Welcomes End to Functional Genus Claims in Amgen Oral Arguments
Recent Posts
- Other Barks & Bites for Friday, March 31: Japan Restricts Chip-Making Exports, Ocado Scores UK High Court Win in Robotic Warehousing Case, and Judge Rejects Fair Use Defense for Internet Archive
- U.S. Government Sides with Teva in Skinny Label SCOTUS Fight
- Industry, NGOs Spar Over Need to Extend TRIPS COVID IP Waiver at ITC Hearing
- Software-Related U.S. Patent Grants in 2022 Remained Steady While Chinese Software Patents Rose 8%
- The Truth Leaks Out: Justices Struggle with the Science, Sanofi Welcomes End to Functional Genus Claims in Amgen Oral Arguments